Rapidly Infusing Oral Mucosal CBD Composition for Fast Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain treatment methods, particularly for neuropathic pain, are inadequate due to the limited effectiveness of opioids, patient intolerance of foul-tasting CBD formulations, inaccurate dosing, and low bioavailability, leading to inconsistent therapeutic outcomes and compliance issues.
Innovation Solution
A lyophilized, rapidly infusing composition formulated with gelatin and sugar alcohol as a binder, designed for oral mucosal administration, which disintegrates within seconds, allowing direct absorption through the sublingual or buccal mucosa, thereby avoiding first-pass metabolism and ensuring high bioavailability and rapid therapeutic onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If CBD is administered orally through traditional formulations, then it can be taken conveniently, but it has low bioavailability and foul taste causing patient intolerance
Solution Approach 1:
The patent changes the physical state of CBD from liquid/oily to solid crystalline form through controlled crystallization processes. This parameter change enables the CBD to be formulated into rapidly dissolving solid dosage forms (tablets, lozenges, orals) that dissolve in seconds, providing both convenience and high bioavailability while eliminating the foul taste associated with liquid CBD formulations
Solution Approach 2:
The patent utilizes phase transitions by converting CBD from liquid phase to solid crystalline phase through controlled cooling and crystallization. This phase transition allows the CBD to be delivered in solid forms that rapidly dissolve in the oral cavity, bypassing the need for oily vehicles and improving both patient acceptance and bioavailability
2Reliability
If opioids are used for neuropathic pain, then pain relief can be achieved, but addiction and tolerance develop leading to frequent sustained use
Solution Approach 1:
The patent extracts and isolates pure CBD from cannabis plant material through controlled crystallization processes, creating a non-intoxicating therapeutic agent that provides pain relief without the addictive properties of THC or opioids. The extraction process removes harmful components while retaining the therapeutic benefits of CBD
3Ease of operation
If CBD is formulated in traditional liquid or oily forms, then it can be administered, but accurate dosing is difficult and patient compliance is poor
Solution Approach 1:
The patent creates disposable single-unit solid dosage forms (tablets, lozenges) containing precise amounts of crystalline CBD. Each unit is pre-dosed accurately and designed for single use, eliminating the need for measuring devices and ensuring consistent dosing. The units dissolve rapidly in the oral cavity, providing convenient administration with precise dosage control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides rapid pain relief with high bioavailability (>50%) and improved patient compliance by minimizing oral residence time, offering a rapid onset of therapeutic effects within minutes.
Implementation Method 1
allowing direct absorption through the sublingual or buccal mucosa
Implementation Method 2
A lyophilized, rapidly infusing composition formulated with gelatin and sugar alcohol as a binder
Data Source
AI summary
A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).